Disulfiram Modulated ROS-MAPK and NFκB Pathways and Targeted Breast Cancer Cells with Cancer Stem Cell-like Properties

Overview

Journal Br J Cancer

Specialty Oncology

Date 2011 Apr 14

PMID 21487404

Citations 174

Authors

N C Yip

I S Fombon

P Liu

S Brown

V Kannappan

A L Armesilla

B Xu

J Cassidy

J L Darling

W Wang

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies indicate that disulfiram (DS), an anti-alcoholism drug, is cytotoxic to cancer cell lines and reverses anticancer drug resistance. Cancer stem cells (CSCs) are the major cause of chemoresistance leading to the failure of cancer chemotherapy. This study intended to examine the effect of DS on breast cancer stem cells (BCSCs).

Methods: The effect of DS on BC cell lines and BCSCs was determined by MTT, western blot, CSCs culture and CSCs marker analysis.

Results: Disulfiram was highly toxic to BC cell lines in vitro in a copper (Cu)-dependent manner. In Cu-containing medium (1 μM), the IC(50) concentrations of DS in BC cell lines were 200-500 nM. Disulfiram/copper significantly enhanced (3.7-15.5-fold) cytotoxicity of paclitaxel (PAC). Combination index isobologram analysis demonstrated a synergistic effect between DS/Cu and PAC. The increased Bax and Bcl2 protein expression ratio indicated that intrinsic apoptotic pathway may be involved in DS/Cu-induced apoptosis. Clonogenic assay showed DS/Cu-inhibited clonogenicity of BC cells. Mammosphere formation and the ALDH1(+VE) and CD24(Low)/CD44(High) CSCs population in mammospheres were significantly inhibited by exposure to DS/Cu for 24 h. Disulfiram/copper induced reactive oxygen species (ROS) generation and activated its downstream apoptosis-related cJun N-terminal kinase and p38 MAPK pathways. Meanwhile, the constitutive NFκB activity in BC cell lines was inhibited by DS/Cu.

Conclusion: Disulfiram/copper inhibited BCSCs and enhanced cytotoxicity of PAC in BC cell lines. This may be caused by simultaneous induction of ROS and inhibition of NFκB.

Citing Articles

Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade.

Yuan M, Shi L, Liu Y, Xiang K, Zhang Y, Zhou Y Int J Biol Sci. 2025; 21(4):1730-1748.

PMID: 39990655 PMC: 11844283. DOI: 10.7150/ijbs.105575.

Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.

Imam M, Ji J, Zhang Z, Yan S Front Pharmacol. 2025; 15:1493188.

PMID: 39867656 PMC: 11757020. DOI: 10.3389/fphar.2024.1493188.

Building of CuO@Cu-TA@DSF/DHA Nanoparticle Targets MAPK Pathway to Achieve Synergetic Chemotherapy and Chemodynamic for Pancreatic Cancer Cells.

Zhang J, Li Z, Xie Z, You S, Chen Y, Zhang Y Pharmaceutics. 2025; 16(12.

PMID: 39771592 PMC: 11680075. DOI: 10.3390/pharmaceutics16121614.

PLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo.

Butcher K, Wang Z, Kurusamy S, Zhang Z, Morris M, Najlah M Biomolecules. 2025; 14(12.

PMID: 39766358 PMC: 11674892. DOI: 10.3390/biom14121651.

Cuproptosis: a promising new target for breast cancer therapy.

Jiang Q, Tong F, Xu Y, Liu C, Xu Q Cancer Cell Int. 2024; 24(1):414.

PMID: 39702350 PMC: 11661134. DOI: 10.1186/s12935-024-03572-2.

References

Cresta S, Sessa C, Catapano C, Gallerani E, Passalacqua D, Rinaldi A . Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer. 2008; 44(13):1829-34. DOI: 10.1016/j.ejca.2008.05.022. View

Eneanya D, BIANCHINE J, Duran D, Andresen B . The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol. 1981; 21:575-96. DOI: 10.1146/annurev.pa.21.040181.003043. View

Alison M, Guppy N, Lim S, Nicholson L . Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?. J Pathol. 2010; 222(4):335-44. DOI: 10.1002/path.2772. View

Lopez-Lazaro M . Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 2006; 252(1):1-8. DOI: 10.1016/j.canlet.2006.10.029. View

Jin Y, Lu Z, Ding K, Li J, Du X, Chen C . Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010; 70(6):2516-27. DOI: 10.1158/0008-5472.CAN-09-3950. View

Margalioth E, Schenker J, Chevion M . Copper and zinc levels in normal and malignant tissues. Cancer. 1983; 52(5):868-72. DOI: 10.1002/1097-0142(19830901)52:5<868::aid-cncr2820520521>3.0.co;2-k. View

Wang W, Cassidy J, OBrien V, Ryan K, Collie-Duguid E . Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res. 2004; 64(22):8167-76. DOI: 10.1158/0008-5472.CAN-04-0970. View

Wang C, Mayo M, Korneluk R, Goeddel D, Baldwin Jr A . NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998; 281(5383):1680-3. DOI: 10.1126/science.281.5383.1680. View

Marchitti S, Deitrich R, Vasiliou V . Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev. 2007; 59(2):125-50. DOI: 10.1124/pr.59.2.1. View

10.

Wang W, Cassidy J . Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells. Br J Cancer. 2003; 88(4):624-9. PMC: 2377173. DOI: 10.1038/sj.bjc.6600753. View

11.

Nobel C, Kimland M, Lind B, Orrenius S, Slater A . Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J Biol Chem. 1995; 270(44):26202-8. DOI: 10.1074/jbc.270.44.26202. View

12.

Sladek N . Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol. 2003; 17(1):7-23. DOI: 10.1002/jbt.10057. View

13.

Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

14.

Storci G, Sansone P, Mari S, DUva G, Tavolari S, Guarnieri T . TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol. 2010; 225(3):682-91. PMC: 2939957. DOI: 10.1002/jcp.22264. View

15.

McCubrey J, Lahair M, Franklin R . Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal. 2006; 8(9-10):1775-89. DOI: 10.1089/ars.2006.8.1775. View

16.

Junttila M, Li S, Westermarck J . Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J. 2007; 22(4):954-65. DOI: 10.1096/fj.06-7859rev. View

17.

Marcato P, Dean C, Pan D, Araslanova R, Gillis M, Joshi M . Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 2011; 29(1):32-45. DOI: 10.1002/stem.563. View

18.

Dalerba P, Cho R, Clarke M . Cancer stem cells: models and concepts. Annu Rev Med. 2006; 58:267-84. DOI: 10.1146/annurev.med.58.062105.204854. View

19.

Xu B, Guo X, Mathew S, Armesilla A, Cassidy J, Darling J . Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Lett. 2009; 291(2):200-8. DOI: 10.1016/j.canlet.2009.10.013. View

20.

Mulay I, Roy R, Knox B, Suhr N, DELANEY W . Trace-metal analysis of cancerous and noncancerous human tissues. J Natl Cancer Inst. 1971; 47(1):1-13. View